SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is driving intense market conversation following its historic IPO, which saw the company achieve a massive valuation on its first day of trading. Community discourse is sharply divided between retail investors optimistic about the stock's long-term potential for space and AI infrastructure, and skeptics who are highlighting the company's lack of profitability, high valuation relative to earnings, and the influence of heavy institutional buying.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is facing intense volatility as investors debate the legitimacy of the project amid broader market skepticism and comparisons to other political-themed assets. The community remains deeply polarized, with active discussions focusing on potential long-term devaluation, concerns over market manipulation, and the speculative nature of the coin.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are surging following reports that the streaming company is exploring strategic options, including a potential sale to a U.S. media entity. Investors are actively debating the viability of these buyout rumors and discussing potential acquirers, while also keeping a close eye on the stock's strong technical momentum.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring the latest developments in the Middle East and shifting labor market data, driving heightened volatility across major indices. Community discussion is focused on the potential impact of ongoing geopolitical tensions and upcoming economic releases on market momentum.

Powerlaw Corp. is a closed-end fund, which engages in investing in artificial intelligence, next-generation software, modern aerospace and defense, and consumer technology platforms. It offers daily liquidity, monthly NAV reporting, quarterly portfolio disclosure, independent governance, and the disclosure standards of a registered investment company. The company was founded on September 9, 2024 and is headquartered in San Francisco, CA.

Powerlaw Corp

Powerlaw Corp is currently under intense scrutiny from the community, with shares experiencing high volatility and significant selling pressure despite the fund's heavy exposure to high-profile private companies like SpaceX and OpenAI. Traders are actively debating whether the recent price decline represents a long-term entry opportunity or a potential pump-and-dump scheme, as they await further updates on the fund's net asset value and the impact of upcoming SpaceX-related market events.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as it navigates significant market volatility driven by a proposed public stock offering, occurring shortly after the company reported successful Phase 3 trial results for its HAE gene-editing therapy. The community is actively debating the strategic necessity of the dilution against the long-term potential of the company's CRISPR pipeline, with many retail traders expressing frustration over management's timing while bulls highlight institutional accumulation and the stock's massive short interest as potential catalysts for a future squeeze.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh the highly anticipated R2 SUV launch against broader concerns regarding production scaling, profitability, and unfavorable lease pricing. While the community remains deeply divided between bulls citing the long-term potential of the R2 platform and bears focusing on weak execution and cash burn, sentiment is currently pressured by a wider market downturn and skepticism over whether the launch acts as a true turning point.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing significant investor attention as it transitions from a legacy film company into a strategic player in domestic pharmaceutical manufacturing and supply chain infrastructure, with community focus centering on anticipated FDA certifications and upcoming earnings. Investors are actively discussing the potential for a massive stock re-rating driven by government onshoring initiatives, tariff impacts on imported drug components, and strategic facility pivots.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as investors monitor ongoing commissioning of its new Thompson Falls smelter and speculate on potential government involvement or partnerships following recent industry events. The community is actively debating the company's long-term critical minerals strategy and execution while navigating persistent price volatility and high short interest in the sector.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending following shareholder approval of the $110 billion merger with Paramount Skydance, a move that is reshaping the streaming landscape while drawing ongoing scrutiny from regulators and industry creators. Investors are actively discussing the deal's path to completion, the impact of significant debt restructuring, and the potential competitive challenges the combined entity will face against industry giants.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire SEATTLE, June 12, 2026 $4.5 million upfront with up to an additional...

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire SEATTLE, June 11, 2026 $4.5 million upfront with up to an additional $12 million of...

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial PR...

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy

Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy PR...

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer Atossa Therapeutics to Host Virtual KOL Event Featuring...

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...

ATOS Stock Jumps 8% Today – An FDA Designation Draws Investor Cheer For Atossa Therapeutics

Equity

The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Atossa’s drug for the treatment of McCune-Albright Syndrome in females.

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.


Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Current Price	$2.46
Prev Close	$2.59
Open	$2.57
Dividend Yield	0.00%
50-Day Moving Average	$5.12
Beta	1.24
Avg. Volume	52,975.81
PE Ratio	-0.56

52-Week High	$19.35
52-Week Low	$2.45
Market Capitalization	$22.26M
EPS (Annual)	-$4.04
Price to Book	0.69
Revenue Per Employee	$0.00

ATOSAtossa Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News